YOLFTbeta
Labiana Health S.A.

Labiana Health S.A.

LAB · MC · Healthcare / Drug Manufacturers - Specialty & Generic

4.80EUR-0.04 (-0.83%)

Price History

Full chart

Market Stats

Previous Close4.84
Open4.84
Day Range4.70 – 4.88
52-Week Range4.00 – 8.20
Volume6.27K
Market Cap50.09M
P/E (TTM)16.39
Forward P/E8.11
EPS0.36
Dividend Yield0.00%
Beta0.16
50-Day Avg6.25
200-Day Avg5.78

About

Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina Labiana brand name. In addition, it offers contract development and manufacturing services. The company was founded in 1958 and is based in Pozuelo de Alarcón, Spain.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Manuel Ramos Ortega
  • Employees373
  • HeadquartersAv. Europa, Pozuelo de Alarcón, Spain, 28023, Spain
  • Websitehttps://www.labiana.com

Leadership

  • Mr. Manuel Ramos OrtegaPresident, CEO & Chairman
  • Mr. Miquel Pujolriu GimenezCFO & Secretary of the Board
  • Cristina Ramos RecoderDirector of Investor Relations
  • Ivana NovoaHR Director
  • Ms. Sandra Villagrasa ClementeExecutive Director
  • Xavier Perez RamosManaging Director of Animal Division
  • Dragoljub MilinkovicManaging Director of Zavod
  • Suva KayaManaging Director of Zoleant

Financials

Income Statement

Currency: EUR2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue57.84M56.96M57.85M58.46M66.26M75.18M
Growth (%)--1.53%+1.57%+1.06%+13.33%+13.47%
Cost of Revenue23.78M21.58M25.36M24.12M25.31M29.21M
Gross Profit34.06M35.37M32.49M34.34M40.94M45.97M
Gross Margin58.88%62.10%56.16%58.74%61.79%61.15%
Operating Expense31.60M34.83M38.72M36.18M35.84M38.67M
Operating Income2.46M539.91K-6.23M-1.84M5.10M7.30M
Operating Margin4.25%0.95%-10.77%-3.16%7.70%9.71%
EBITDA---894.29K3.11M9.06M10.90M
EBITDA Margin---1.55%5.32%13.68%14.50%
Net Income1.07M-1.78M-8.94M-4.42M253.45K2.57M
Net Income Margin1.86%-3.12%-15.46%-7.57%0.38%3.42%
Interest Expense-2.13M2.11M3.29M4.84M5.91M
Interest Expense % of Total Revenue-3.74%3.64%5.62%7.30%7.86%

Balance Sheet

Currency: EUR2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets68.37M60.78M59.12M52.00M57.54M
Total Liabilities56.84M53.04M55.72M49.43M52.79M
Total Equity11.59M7.74M3.58M2.87M5.08M
Cash3.28M2.52M2.96M6.74M5.91M
Net Debt39.17M33.57M37.21M27.75M30.09M

Cash Flow

Currency: EUR2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow3.91M4.68M-1.83M7.19M1.70M
Investing Cash Flow--2.95M---
Financing Cash Flow--2.50M---
Capital Expenditure4.77M5.45M2.85M3.05M4.44M
Free Cash Flow-858.72K-774.37K-4.68M4.15M-2.74M
FCF to OCF-21.98%-16.55%256.13%57.63%-161.08%

Key Statistics & Ratios

Market Cap50.09M
Enterprise Value81.69M
Trailing P/E16.39
Forward P/E8.11
PEG Ratio0.16
Price / Sales0.66
Price / Book10.02
EPS0.36
Book Value0.814
Revenue (TTM)76.44M
Gross Profit (TTM)43.87M
EBITDA9.66M
Profit Margin3.36%
Operating Margin5.64%
Return on Equity69.74%
Return on Assets8.28%
Shares Outstanding8.49M
Shares Float2.10M
Beta0.16
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%